Electron-Neutrino Bremsstrahlung in Electro-Weak Theory

The electron-neutrino bremsstrahlung process has been considered in the framework of electro-weak theory. The scattering cross section has been calculated in the center of mass frame and approximated to extreme relativistic as well as non-relativistic case. The rate of energy-loss via this type of bremsstrahlung process has been obtained both in non-degenerate and degenerate region. The effect of this electron-neutrino bremsstrahlung process in different ranges of temperature and density characterizing the late stages of stellar evolution has been discussed. It is found from our study that this bremsstrahlung process is highly important in the non-degenerate region, although it might have some significant effect in the extreme relativistic degenerate region.Comment: 18 pages including 4 figures and 1 table; Published in J. Phys

Bremsstrahlung neutrinos from electron-electron scattering in a relativistic degenerate electron plasma

We present a calculation of neutrino pair bremsstrahlung due to electron-electron scattering in a relativistic degenerate plasma of electrons. Proper treatment of the in-medium photon propagator, i.e., inclusion of Debye screening of the longitudinal part and Landau damping of the transverse part, leads to a neutrino emissivity which is several orders of magnitude larger than when Debye screening is imposed for the tranverse part. Our results show that this in-medium process can compete with other sources of neutrino radiation and can, in some cases, even be the dominant neutrino emission mechanism. We also discuss the natural extension to quark-quark bremsstrahlung in gapped and ungapped quark matter.Comment: 15 pages, 7 figure

Can Treatable Traits Be the Approach to Addressing the Complexity and Heterogeneity of COPD?

the complexity of COPD implies the need to identify groups of patients with similar clinical characteristics and prognosis or treatment requirements. this is why much attention has been paid to identifying the different clinical phenotypes by investigating the clinical expression of the disease, and endotypes by studying the biological networks that enable and limit reactions. however, this approach is complicated because one endotype gives rise to one or more clinical characteristics, and clinical phenotypes can be derived from several endotypes. to simplify the approach, a new taxonomic classification of COPD based on the different causes (or etiotypes) has been proposed, but these etiotypes have not yet been validated. a simpler method is the so-called tractable traits approach, which is free from any designation of the disorder to be treated and does not present the criticality of using etiotypes. a large randomised controlled trial on using the treatable traits approach in COPD is still lacking. nevertheless, this approach is already applied by following the GOLD strategy. however, its application is complicated because several potentially treatable traits have been identified within the pulmonary domain, the extrapulmonary domain, and the behavioural/risk factor domain. In addition, the hierarchy of the dominant treatable traits has not yet been established, and they change over time both spontaneously and because of treatment. This means that the patients being treated according to the tractable traits approach must be constantly followed over time so that the therapy is focused on their temporal needs

Pharmacological management of COVID-19 patients with ARDS (CARDS): A narrative review

Coronavirus disease 2019 (COVID-19) is highly infectious. It has been highlighted that if not expertly and individually managed with consideration of the vasocentric features, a COVID-19 patient with an acute respiratory distress syndrome (CARDS) may eventually develop multiorgan failure. Unfortunately, there is still no definite drug for CARDS that is capable of reducing either short-term or long-term mortality and no specific treatments for COVID-19 exist right now. In this narrative review, based on a selective literature search in EMBASE, MEDLINE, Scopus, The Cochrane Library, Web of Science, and Google Scholar and ClinicalTrials.gov, we have examined the emerging evidence on the possible treatment of CARDS. Although numerous pharmacologic therapies to improve clinical outcomes in CARDS have been studied also in clinical trials, none have shown efficacy and there is great uncertainty about their effectiveness. There is still no recommendation for the therapeutic use of any specific agent to treat CARDS because no drugs are validated to have significant efficacy in clinical treatment of COVID-19 patients in large-scale trials. However, there exist a number of drugs that may be useful at least in some patients. The real challenge now is to link the right patient to the right treatment

Summary of International Transport Energy Modeling Workshop

The NextSTEPS program at ITS-Davis convened a one-day workshop on international transportation energy modeling (iTEM), focused on comparing the frameworks and scenario projections from four major global transport models: -- Global Change Assessment Model (GCAM) by Pacific Northwest National Laboratory (PNNL) and ITS-Davis, -- MESSAGE-Transport (Model for Energy Supply Strategy Alternatives and their General Environmental Impact) by the International Institute for Applied Systems Analysis (IIASA), -- Mobility Model (MoMo) by the International Energy Agency, and -- Roadmap by the International Council on Clean Transportation (ICCT). Highlights: -- Projections of "baseline" global transportation energy use rise from 98 EJ in 2010 to 160-250 EJ by 2050. -- There are considerable differences in historical data for some modes, both globally and for individual countries (particularly non-OECD countries). Variability in estimates of transportation activity are in most cases much larger than energy differences. -- Global average vehicle ownership rates are projected to range from 270 to 450 per 1,000 people by 2050 with wide ranges across countries: 700-1,075 for the US by the middle of the century (US is around 700 today), 100-650 for China, and 80-380 for India across four models. -- All models rely mainly on GDP to estimate the future demand for freight and hold the base year modal shares (e.g. truck v. rail) roughly constant through 2050. In reality, future evolution will depend on characteristics of products (e.g. type of commodities) being shipped, technologies available for freight and their efficiencies, and policies and infrastructure. -- Current policy commitments toward EVs, PHEVs and H2FCVs (and thus baseline projections) maybe below the numbers suggested by iTEM models as required for meeting climate targets (e.g., 2 degrees C). -- Improvements in data quality and the representation of car ownership and use across the models were identified as priorities. Modeling transport energy use can either be done by estimating how far people travel and what mode of transportation they choose or by estimating how many vehicles there are and how far each one travels. These are complementary approaches, and in theory they should both lead to the same answer. The former approach, used in "service demand" models, seem more intuitive when one wants to model societal shifts in modes of transportation, either in emerging economies as they develop or in developed economies as they decarbonize; but collecting data on service demand is notoriously difficult. In contrast, vehicle stock models use readily-available vehicle sales data, but are harder to use in future-state, what-if scenarios (particularly in estimating modal shift behaviors) and thus require special attention by experts. The four iTEM models are different in terms of scope (GCAM and MESSAGE cover all sectors of the energy system vs. MoMo and Roadmap which cover transportation only) and model structure (GCAM and MESSAGE rely on internal drivers, particularly the costs of technology and travel, to project future changes whereas MoMo and Roadmap rely on experts' judgments and detailed analysis of technology and policies to drive long-term changes). Yet, owing to these differences, the models are highly complementary and in some cases can be used jointly to answer questions that no single model can tackle on its own. The following summary shares some of the comparisons and findings from the workshop

Effect of formoterol/budesonide combination on arterial blood gases in patients with acute exacerbation of COPD

n/

SPINAL MUSCLE ACTIVITY DURING DIFFERENT RUGBY SCRUM ENGAGEMENT PROCEDURES

Biomechanical studies of rugby union scrummaging have focussed on kinetic and kinematic analyses, whilst muscle activation strategies employed by front row players during scrummaging are still unknown. The aim of this study was to investigate the activity of the sternocleidomastoid, upper trapezius and erector spinae muscles during machine and live scrums. Nine male front-row forwards scrummaged individually against a scrum machine under „crouch-touch-set? and „crouch-bind-set? conditions, and against a two-player opposition in a simulated live condition. Results suggest that the pre-bind technique, may effectively prepare the cervical spine by stiffening joints before the impact phase. Additionally, machine scrummaging does not replicate the muscular demands of live scrummaging for the erector spinae

Use of human airway smooth muscle in vitro and ex vivo to investigate drugs for the treatment of chronic obstructive respiratory disorders

Isolated airway smooth muscle has been extensively investigated since 1840 to understand the pharmacology of airway diseases. There has often been poor predictability from murine experiments to drugs evaluated in patients with asthma or chronic obstructive pulmonary disease (COPD). However, the use of isolated human airways represents a sensible strategy to optimise the development of innovative molecules for the treatment of respiratory diseases. This review aims to provide updated evidence on the current uses of isolated human airways in validated in vitro methods to investigate drugs in development for the treatment of chronic obstructive respiratory disorders. This review also provides historical notes on the pioneering pharmacological research on isolated human airway tissues, the key differences between human and animal airways, as well as the pivotal differences between human medium bronchi and small airways. Experiments carried out with isolated human bronchial tissues in vitro and ex vivo replicate many of the main anatomical, pathophysiological, mechanical and immunological characteristics of patients with asthma or COPD. In vitro models of asthma and COPD using isolated human airways can provide information that is directly translatable into humans with obstructive lung diseases. Regardless of the technique used to investigate drugs for the treatment of chronic obstructive respiratory disorders (i.e., isolated organ bath systems, videomicroscopy and wire myography), the most limiting factors to produce high-quality and repeatable data remain closely tied to the manual skills of the researcher conducting experiments and the availability of suitable tissue